Dianthus Therapeutics, Inc.’s Post

Today, we reported our Q2 2024 financial results and highlighted recent business achievements. “The second quarter of 2024 highlighted the Dianthus team’s continued focus on execution and operational excellence as we advance our clinical programs for DNTH103 in generalized Myasthenia Gravis, Multifocal Motor Neuropathy, and Chronic Inflammatory Demyelinating Polyneuropathy,” said Marino Garcia, Chief Executive Officer of Dianthus Therapeutics. “We believe DNTH103 may be a potentially best-in-class, potent classical complement pathway inhibitor with infrequent, subcutaneous self-administration and a differentiated safety profile across our three initial indications of gMG, MMN and CIDP. We continue to be confident in the pipeline-in-a-product potential of DNTH103 across multiple autoimmune diseases, supported by our proof-of-concept 𝘪𝘯 𝘷𝘪𝘵𝘳𝘰 data presented at EAN and recent competitor clinical data that further validate targeting the classical pathway and active C1s.” https://lnkd.in/eSkS37Q4

🚨 Hot Job Alert! 🚨 We are #hiring a Director, Drug Safety Operations. You will work closely with Doreen G. to oversee and develop safety operations activities. You will partner with internal and external global teams supporting our three clinical programs, as we work together on the development of next-generation antibody #ComplementTherapeutics. To join us, learn more and #apply here: https://lnkd.in/euYZRz-W

🚨 Hot Job Alert! 🚨 We are #hiring a Senior Medical Director, Drug Safety and Pharmacovigilance. You will be leading the analysis of safety data, identifying, detecting and investigating safety signals, as well as evaluating and proactively managing risk, as we advance the development of next-generation antibody #ComplementTherapeutics. To join us, learn more and #apply here: https://lnkd.in/etmY5eEe

We asked our team how they’d describe Dianthus,  take a look at some of their responses! For the second year in a row, the top 3 words were Open, Collaborative, and Supportive, with two new additions, Motivated and Ambitious! As our company evolves, we aim to continue cultivating an environment where our employees thrive and #GrowTogether. Visit dianthustx.com/careers to learn more about our mission, culture, and opportunities to join our team! #biotech #teamwork #employeeengagement

Happy Independence Day! We wish everyone a safe and joyous holiday.

🚨 Hot Job Alert! 🚨 We are #hiring a Senior Director, Biostatistics. You will be developing and executing our #biostats strategy for multiple clinical programs as we advance the development of next-generation antibody #ComplementTherapeutics. To join us, learn more and #apply here: https://lnkd.in/edk9Fb4a

We are excited to announce two poster presentations for DNTH103 at the 10th Congress of the European Academy of Neurology (EAN) in Helsinki.   June 29, 2024, 14:10 EEST DNTH103, Investigational Therapy for Generalised Myasthenia Gravis Session: Muscle and Neuromuscular Junction Disorder 1; Presentation Number: EPR-118 June 30, 2024, 14:25 EEST DNTH103: Preventing Nerve Damage in a CIDP Model via Sustained Complement Inhibition Session: Muscle and Neuromuscular Junction Disorder 2; Presentation Number: EPR-243 These posters will be made available after they are presented on the Dianthus website: https://lnkd.in/gZz2x_tw DNTH103 is an investigational agent that is not approved as a therapy in any indication in any jurisdiction worldwide. #ean2024 #neurology

We are always looking for the most passionate and innovative individuals, so our team comes from all over the nation! With our combination of #remote and #hybrid roles, our team now spans across 11 states, including two team members across the pond. Look out for our Hot Job Alerts and visit dianthustx.com/careers to learn more about how we #GrowTogether! #hiring #biotechjobs #GrowWithUs

As a chronic neuromuscular disease, #MyastheniaGravis causes weakness in the voluntary muscles. It affects both men and women and occurs across all racial and ethnic groups. We are #MGStrong and committed to advancing the next generation of #ComplementTherapeutics with the potential to treat patients living with generalized Myasthenia Gravis.